昂利康(002940.SZ):與川寧生物簽訂長期戰略合作協議 具備較穩定的產業鏈保障
格隆匯7月12日丨昂利康(002940.SZ)近期在接待機構投資者調研時表示,公司與川寧生物簽訂了長期戰略合作協議,具備了較為穩定的產業鏈保障。公司未來將從傳統的頭孢拉定、頭孢氨苄、頭孢克洛三個品種逐步拓展其他頭孢原料藥品種,並努力實現已有頭孢原料藥的產品製劑全覆蓋;工藝方面,頭孢氨苄、頭孢克洛已實現運用酶法技術的規模化生產,剩下的頭孢原料藥品種正在進行工藝的優化和變更,未來計劃都將實現酶法技術規模化生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.